A convergent mixed-methods study at King Chulalongkorn Memorial Hospital evaluated real-world use of quarterly intravenous eptinezumab and found that it reduced monthly migraine days and disability over six months. The report also identifies high cost and delivery logistics as major barriers to broader use. Researchers observed clinically meaningful improvements while assessing feasibility through patient and health system perspectives. The paper highlights a common pattern in modern migraine therapeutics: effectiveness in practice can still be constrained by access and budget structures. For payers and provider networks, the findings frame eptinezumab as a treatment that may require policy and service-design adjustments to avoid limiting who can benefit.